Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVErsing Airway Remodelling With Tezepelumab (REVERT)
NCT05651841Phase 3Completed
- Sponsor
- CHU Montpellier
- Start
- Mar 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tezepelumab in asthma (3 arms), sponsored by CHU Montpellier. Primary endpoint: Percentage Bronchial Wall Area at 6 months. Started Mar 2023; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05651841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651841.